Scandinavian journal of gastroenterology
-
Scand. J. Gastroenterol. · Apr 2004
Clinical Trial Controlled Clinical TrialGlucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1.
GLP-1 (glucagon-like peptide-1) and GLP-2 (glucagon-like peptide-2) are released in equimolar amounts in response to meal ingestion. GLP-1 inhibits gastric emptying and reduces postprandial gastric and exocrine pancreatic secretion and may play a physiological regulatory role in controlling appetite and energy intake in humans. The role of GLP-2 is more uncertain. Based on the results of animal studies, it has been suggested that GLP-2 may induce intestinal epithelial growth and inhibit gastric motility. The aim of this study was to determine to what extent GLP-2 alone or together with GLP-1 inhibits gastric emptying and the sensation of hunger in man. ⋯ Both GLP-1 and GLP-2 inhibit antral emptying in man, but GLP-1 is more potent.